Prostate Cancer Clinical Trials in New York, New York

70 studies are recruiting for prostate cancer in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

    The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally adv…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, New York, New York
    Locations
    346 in total
    Run by
    AstraZeneca

    See if you can join NCT06952803 on ClinicalTrials.gov

  2. Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer

    In this study the investigators will find out whether the use of a new type of boost approach called irreversible electroporation (IRE) is as effective as the standard boost approach of radiation therapy for participants with intermediate-risk prostate cancer receiving standard stereotactic body ra…

    Stage
    Phase 3
    Ages
    Any age
    Site
    Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York, New York
    Locations
    8 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07548164 on ClinicalTrials.gov

  3. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

    This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Hospital, New York, New York
    Locations
    90 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT06172478 on ClinicalTrials.gov

  4. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

    Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Icahn School of Medicine at Mount Sinai ( Site 0009), New York, New York
    Locations
    298 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06925737 on ClinicalTrials.gov

  5. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage
    Phase 1
    Ages
    12 and older
    Site
    Memorial Sloan Kettering, New York, New York
    Locations
    77 in total
    Run by
    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

  6. PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

    PROMISE aims to create a comprehensive nationwide registry of prostate cancer patients with germline pathogenic variants by prospectively screening approximately 5,000 subjects with a confirmed prostate cancer diagnosis, either through tissue biopsy, PSA greater than 100 ng/dL and/or radiographic e…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    3 in total
    Run by
    Prostate Cancer Clinical Trials Consortium

    See if you can join NCT04995198 on ClinicalTrials.gov

  7. MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

    The purpose of this study is to find out if giving radiation therapy (RT) to areas of metastatic prostate cancer at the time a participant is diagnosed will help control disease better than the usual treatment. This treatment is called metastasis-directed radiotherapy (MDRT). The usual treatment fo…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    3 in total
    Run by
    Case Comprehensive Cancer Center

    See if you can join NCT06150417 on ClinicalTrials.gov

  8. A Study of Changes to Prostate Procedures

    The purpose of this study is to look whether using local anesthesia during a transperineal prostate biopsy, while put to sleep by IV sedation, helps reduce the number of people who feel significant pain in the recovery room. The researchers will also look at how local anesthesia affects the amount …

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06986083 on ClinicalTrials.gov

  9. The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

    The goal of this clinical trial is to measure the toxicity and effectiveness of the following treatments for cFIR/cgUIR prostate cancer patients. Stereotactic body radiotherapy (SBRT) alone or Stereotactic body radiotherapy (SBRT) combined with Ultrashort GNRH Antagonist called Relugolix (an oral d…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    4 in total
    Run by
    Yale University

    See if you can join NCT06111781 on ClinicalTrials.gov

  10. Sacral Neuromodulation for Male Overactive Bladder (MOAB)

    To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Integrated Medical Professionals, New York, New York
    Locations
    23 in total
    Run by
    Axonics, Inc.

    See if you can join NCT06511141 on ClinicalTrials.gov

  11. [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate or Salivary Gland Cancer

    This study will use PET scans, which is a type of x-ray test that uses a radiotracer, to see whether these scans may be better able to find places in the body where your prostate cancer may have spread.

    Stage
    Not phased
    Ages
    Any age
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT00588185 on ClinicalTrials.gov

  12. Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

    The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Mount Sinai Doctors Urology Faculty Practice, New York, New York
    Locations
    34 in total
    Run by
    Clarity Pharmaceuticals Ltd

    See if you can join NCT06056830 on ClinicalTrials.gov

  13. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York, New York
    Locations
    39 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06465069 on ClinicalTrials.gov

  14. Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer

    For this study, high risk prostate cancer patients with lower risk ARTERA scores will be treated with 6 months of Androgen Deprivation Therapy (ADT) in conjunction with dose escalated radiotherapy to the prostate and nodes. Specifically, patients enrolled in this study will undergo one of several d…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    NYU Langone Health, New York, New York
    Run by
    NYU Langone Health

    See if you can join NCT07801664 on ClinicalTrials.gov

  15. Researching the Effect of Exercise on Cancer

    Researchers think that exercise may be able to prevent cancer from coming back by lowering ctDNA levels. The purpose of this study is to explore how aerobic exercise (exercise that stimulates and strengthens the heart and lungs and improves the body's use of oxygen) can reduce the level of ctDNA fo…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    9 in total
    Run by
    City of Hope Medical Center

    See if you can join NCT04589468 on ClinicalTrials.gov

  16. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

    Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conduc…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    New York Cancer & Blood Specialists, New York, New York
    Locations
    10 in total
    Run by
    Nammi Therapeutics Inc

    See if you can join NCT06582017 on ClinicalTrials.gov

  17. Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

    The purpose of this study is to determine whether [225Ac]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of stand…

    Stage
    Phase 3
    Ages
    18 to 100
    Site
    Weill Cornell Medicine NY-Presb, New York, New York
    Locations
    95 in total
    Run by
    Novartis Pharmaceuticals

    See if you can join NCT06855277 on ClinicalTrials.gov

  18. PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound

    The purpose of this study is to compare the sensitivity of PSMA PET/MRI and standard MRI in detecting focal therapy failure in the prostate one year after High-Intensity Focused Ultrasound (HIFU) treatment. Specifically, the study aims to evaluate whether PSMA PET/MRI offers a higher sensitivity th…

    Stage
    Not phased
    Ages
    40 to 95
    Site
    NYU Langone Health, New York, New York
    Run by
    NYU Langone Health

    See if you can join NCT07184970 on ClinicalTrials.gov

  19. Precision-Based Genomics in Prostate Cancer

    Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect how aggressive the disease is. Objective: To look at gene m…

    Stage
    Not phased
    Ages
    18 to 120
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    11 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT04706663 on ClinicalTrials.gov

  20. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

    The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10 (09 July 2025), only Parts 4A expansion, 6, and 7 a…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    57 in total
    Run by
    Amgen

    See if you can join NCT04221542 on ClinicalTrials.gov

  21. A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

    This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan-Kettering Cancer Center (Mskcc), New York, New York
    Locations
    19 in total
    Run by
    Pathos AI, Inc.

    See if you can join NCT06785636 on ClinicalTrials.gov

  22. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    33 in total
    Run by
    Parabilis Medicines, Inc.

    See if you can join NCT05919264 on ClinicalTrials.gov

  23. This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

    This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Evelyn H. Lauder Breast and Imaging Center (BAIC)., New York, New York
    Locations
    337 in total
    Run by
    Pfizer

    See if you can join NCT07028853 on ClinicalTrials.gov

  24. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

    Stage
    Phase 1
    Ages
    18 to 100
    Site
    NYU Langone Health, New York, New York
    Locations
    36 in total
    Run by
    Janux Therapeutics

    See if you can join NCT05519449 on ClinicalTrials.gov

  25. Prospective Database of Clinical Outcomes Following Cryotherapy for Ablation of Clinically Localized Prostate Cancer

    This will be a prospectively maintained research database. The purpose is to record baseline parameters and treatment outcomes following of Cryotherapy for ablation of clinically localized prostate cancer.

    Stage
    Not phased
    Ages
    40 to 85
    Site
    NYU Langone Health, New York, New York
    Run by
    NYU Langone Health

    See if you can join NCT07184957 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.